Global Cord Blood (NYSE:CO) Receives New Coverage from Analysts at assumed coverage on shares of Global Cord Blood (NYSE:COFree Report) in a research report sent to investors on Saturday morning. The brokerage issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Stock Performance

Shares of CO opened at $1.25 on Friday. The company’s 50 day simple moving average is $1.24 and its 200-day simple moving average is $1.36. The firm has a market cap of $151.94 million, a PE ratio of 1.95 and a beta of 0.16. Global Cord Blood has a 12-month low of $2.03 and a 12-month high of $5.50.

About Global Cord Blood

(Get Free Report)

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.

Further Reading

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with's FREE daily email newsletter.